Last reviewed 2026-04-19 · How we verify

CEFUZONAM

Phase 2 active Small molecule

CEFUZONAM is a drug. It is currently in Phase 2 development.

Cefuzonam works by inhibiting bacterial cell wall synthesis.

Cefuzonam is a small molecule antibiotic developed by Hoechst Marion Roussel, currently owned by Sanofi. Its target and drug class are unknown. It has a half-life of 1.14 hours. Cefuzonam is not FDA approved for any indications. Its commercial status, generic manufacturers, and patent status are also unknown.

Likelihood of approval

17.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Anti-infectives pathway favourability +2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CEFUZONAM
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like houses, and the bacteria are like construction workers trying to build new houses. Cefuzonam stops the construction workers from making the walls of the new houses, effectively preventing the bacteria from growing and multiplying.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CEFUZONAM CI brief — competitive landscape report
CEFUZONAM updates RSS · CI watch RSS

Frequently asked questions about CEFUZONAM

What is CEFUZONAM?

CEFUZONAM is a Small molecule drug.

How does CEFUZONAM work?

Cefuzonam works by inhibiting bacterial cell wall synthesis.

What development phase is CEFUZONAM in?

CEFUZONAM is in Phase 2.

Therapeutic area: All drugs in Infectious Disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing